Yuheng Pharmaceuticals: Wholly-owned subsidiary Methotrexate Injection approved for market listing.

Yuheng Pharmaceutical announced that its wholly-owned subsidiary, Harbin Yuheng Pharmaceutical Co., Ltd., has received the "Drug Registration Certificate" issued by the National Medical Products Administration for its multi-specification injection of methotrexate. This drug is used to treat severe, refractory, disabling psoriasis and active rheumatoid arthritis in adults who have inadequate response to other treatment methods. The product approved this time by Yuheng Pharmaceuticals is the first domestically produced pre-filled methotrexate injection, with strong demand for medication and great market potential.